Completed
The National Academies’ Forum on Neuroscience and Nervous Systems Disorders hosted a workshop on September 10, 2024, they brought together diverse perspectives to examine the promising but understudied applications of GLP-1R agonists in neurological and psychiatric disorders. Experts reviewed the current knowledge and research gaps about how GLP-1R agonists work and evidence of their clinical efficacy for neurodegenerative diseases, substance use disorders, and pain. Attendees from academia, industry, government, and nonprofits also explored regulatory challenges/opportunities in repurposing these drugs for brain conditions.
Featured publication
Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop
Proceedings
·2025
Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have recently received a lot of national attention. Repurposing GLP-1R agonists to treat some central nervous...
View details